Sangamo Therapeutics (SGMOQ) Non-Current Deferred Tax Liability (2013 - 2025)

Sangamo Therapeutics has reported Non-Current Deferred Tax Liability for 9 years, with the latest figure at $15000.0 in Q1 2025.

• On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $15000.0 in Q1 2025; TTM through Mar 2025 was $15000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $5.8 million, down 79.51% from the prior year.
• Non-Current Deferred Tax Liability was $15000.0 for Q1 2025 at Sangamo Therapeutics, down from $5.8 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $31.2 million in Q4 2021, with the low at $15000.0 in Q1 2025.
• Average Non-Current Deferred Tax Liability over 4 years is $10.0 million, with a median of $6.5 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2023: Non-Current Deferred Tax Liability rose 6.61% in 2021, then slumped 79.51% in 2023.
• Over 4 years, Non-Current Deferred Tax Liability stood at $31.2 million in 2021, then fell by 9.84% to $28.1 million in 2022, then plunged by 79.51% to $5.8 million in 2023, then sank by 99.74% to $15000.0 in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $15000.0 (Q1 2025), $5.8 million (Q4 2023), and $6.4 million (Q1 2023), per Business Quant data.